Sign in

Tigem

@tigem.bsky.social
150 followers 436 following 38 posts

The Telethon Institute of Genetics and Medicine (TIGEM) is a Telethon Foundation research center located in Pozzuoli (Italy) that aims to help people with rare genetic disorders across the world.

PostsRepliesMedia
Tigem @tigem.bsky.social · 28/10/2025
🌍Learn more and apply www.rarefind-cofund.eu
000
Tigem @tigem.bsky.social · 28/10/2025
👇 RAREFIND Supervisors cover a wide range of research topics — explore them below and on the website to find the one that sparks your curiosity the most. Join a vibrant scientific community and play an active role in shaping the next discoveries of field!
100
Tigem @tigem.bsky.social · 28/10/2025
🎓Are you looking to pursue a #PhD and make real impact in science? The new RAREFIND #MSCA-COFUND PhD Program offers a unique opportunity to dive into cutting-edge #genetherapy and #celltherapy research with top-tier, interdisciplinary training across 22 leading labs at TIGEM and SR-Tiget.
110
Tigem @tigem.bsky.social · 06/10/2025
🚀 Launch your career in advanced gene and cell therapies! 🚀 RAREFIND #MSCA-COFUND #PhD Programme opens its call for applications! 👉Know more and apply now: www.rarefind-cofund.eu #RAREFINDPhD
021
Reposted by Tigem
di Bernardo Lab @diegodibi.bsky.social · 10/09/2025
Join our lab dibernardo.tigem.it for the #ERC-funded project DIMERCIRCUITS at @tigem.bsky.social. We are building synthetic gene circuits to power next-generation gene and cell therapies. We are looking for candidates with a PhD in #SyntheticBiology or related. Apply by email: dibernardo@tigem.it
022
Tigem @tigem.bsky.social · 03/06/2025
#genetherapy #celltherapy #geneediting #genomics #molecularmedicine #proteindesign #syntheticbiology #AI-basedproteinengineering #computationalbiology #molecularimmunology
000
Tigem @tigem.bsky.social · 03/06/2025
👉 Group Leader positions at TIGEM: www.tigem.it/newsroom/car... 👉 Group Leader positions at San Raffaele Telethon Institute for Gene Therapy (SR-Tiget): back.fondazionetelethon.it/uploads/2025... 👉 Postdoctoral Fellowships at TIGEM & SR-Tiget : back.fondazionetelethon.it/uploads/2025...
back.fondazionetelethon.it
101
Tigem @tigem.bsky.social · 03/06/2025
📢 Global Call for Scientific Talent – Join the #FondazioneTelethon Institutes! We're looking for exceptional scientists to join #TIGEM and #SR-Tiget, two world-class research centers at the forefront of innovation in #genetherapy, #celltherapy, #geneediting, #genomics, and #molecularmedicine.
110
Tigem @tigem.bsky.social · 19/05/2025
Back From #ASGCT!!! TIGEM was pleased to take part in the ASGCT Conference 2025, where we had the opportunity to present our latest research and engage with the gene and cell therapy community! @asgct.bsky.social
000
Tigem @tigem.bsky.social · 16/05/2025
🌍 Attending #ASGCT2025 in #NewOrleans? Don’t miss this Scientific Symposium hosted by the Coalition of International Gene Therapy Societies: 📌 Clinical Trials Around the Globe 🗓️ [Today, May 16th] 🕗 8:00 AM – 9:45 AM 📍 Room 293–296 #GeneTherapy #ASGCT #AAV #Retina #LiverGeneTherapy #RareDisease
011
Tigem @tigem.bsky.social · 15/05/2025
#MPSAwarenessDay #MPSVI #GeneTherapy #RareDiseases #LysosomalDisorders #TIGEM #FondazioneTelethon #MEUSIX #ClinicalTrials #TranslationalResearch #HopeForRare
000
Tigem @tigem.bsky.social · 15/05/2025
📈 Thanks to Fondazione Telethon, a new trial phase is underway — testing a higher dose and pushing us closer to real impact. 🙏 Deep gratitude to the MPS community for their strength and partnership.
100
Tigem @tigem.bsky.social · 15/05/2025
🧬 Through the MEUSIX project with @biomarinpharma.bsky.social and @ec.europa.eu funding, we launched the first AAV-based gene therapy trial for MPS VI — showing promising safety and efficacy. Why gene therapy? Because current treatments fall short. We aim for a one-time, lasting solution.
100
Tigem @tigem.bsky.social · 15/05/2025
🎗️ It’s MPS Awareness Day. At TIGEM, we stand with patients — especially those with MPS VI (Maroteaux-Lamy syndrome), a rare lysosomal disorder caused by ARSB gene mutations.
100
Tigem @tigem.bsky.social · 09/05/2025
📢Applications for SEMM PhD program are now open! 🎉 We have 2 open positions at TIGEM in the PhD program in Systems Medicine. Deadline: June 9th – don’t miss it! Apply here: www.semm.it/education/ho... #PhD #SystemsMedicine #TIGEM #SEMM #PhDOpportunity #BiomedicalResearch #CallForApplications
021
Tigem @tigem.bsky.social · 18/04/2025
🗓️ August 11–12, 2025 | Irvine, California 🧠 Abstract submissions open until April 28! 👉 Info & registration: www.aiche.org/sbe/conferen... #mSBW2025 #SyntheticBiology #GenomicMedicine
aiche.org
2025 International Mammalian Synthetic Biology Workshop (mSBW)
The International Mammalian Synthetic Biology Workshop (mSBW) brings together leaders in synthetic biology with experts from other relevant fields to highlight and inspire cutting-edge synthetic biolo...
010
Tigem @tigem.bsky.social · 18/04/2025
Excited for the International Mammalian Synthetic Biology Workshop (mSBW2025) — the only conference fully focused on mammalian synthetic biology! 🧬 Meet top experts, including @diegodibi.bsky.social, Genomic Medicine Program Coordinator at TIGEM and part of this year’s Organizing Committee.
101
Tigem @tigem.bsky.social · 15/04/2025
#PompeDay #RareDiseaseResearch #GeneTherapy #Tigem #FondazioneTelethon #LisosomalStorageDisorder
000
Tigem @tigem.bsky.social · 15/04/2025
Our journey began with science and compassion, inspired by the story of Rossella and a life-changing connection between Dr. Giancarlo Parenti and John Crowley in 2002 — a reminder that research, collaboration, and care can transform lives. Read the full story here: www.tigem.it/newsroom/new...
100
Tigem @tigem.bsky.social · 15/04/2025
from biomarkers discovery and lysosomal biology insights to innovative gene therapy and chaperone-based approaches.
100
Tigem @tigem.bsky.social · 15/04/2025
Today we mark #InternationalPompeDiseaseDay, raising awareness for this rare genetic disorder. At TIGEM, supported by #FondazioneTelethon, we combine genetics, molecular biology, clinical research, and patient advocacy to advance new therapies —
100
Tigem @tigem.bsky.social · 15/04/2025
Excited to share the latest work of Pastore group! Loss of Folliculin drives liver cell damage and cholangiocarcinoma via MiT/TFE activation. 👉 Read the full article: doi.org/10.1038/s414...
doi.org
Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation - Cell Death & Differentiation
Cell Death & Differentiation - Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation
011
Tigem @tigem.bsky.social · 02/04/2025
#StructuralBiology #AI #GeneTherapy #RareDiseases #ProteinDesign
000
Tigem @tigem.bsky.social · 02/04/2025
💡 "TIGEM gave me the chance to return to Italy and make a difference. I want to push the boundaries of research on rare diseases." Big things ahead for Andrea and his mission to advance molecular therapies! 🚀 Read the interview here: www.tigem.it/newsroom/new...
tigem.it
AI, Biophysics & Rare Diseases: Andrea Pasquadibisceglie’s Mission at TIGEM
110
Tigem @tigem.bsky.social · 02/04/2025
🔬 From Sweden to Italy: @andpdb.bsky.social is bringing his expertise in Computational Structural Biology back home! After working at #KTH (Stockholm), he’s now a Staff Scientist at TIGEM, using AI and physics-based models to design hyperactive enzymes that improve gene therapy for rare diseases.
110
Tigem @tigem.bsky.social · 02/04/2025
A huge thank you to everyone who participated! Let’s keep building bridges between science, finance, and the future. 🌍✨ #HydeParkCoroglio #Innovation #ScienceAndFinance #Collaboration #Future Read more here: www.linkedin.com/feed/update/...
linkedin.com
#hydeparkcoroglio #research #biotechnology #technologytransfer… | Tigem
🎉 We are thrilled to share the success of the latest #HydeParkCoroglio event, featuring our esteemed Prof. Alberto Auricchio, Scientific Director at Tigem in…
000
Tigem @tigem.bsky.social · 02/04/2025
He shared valuable insights on #research and #biotech, exploring the potential of innovation and the challenges ahead. The discussion also covered key financial strategies supporting cutting-edge research, demonstrating how #techtransfer can turn discoveries into real-world impact.
100
Tigem @tigem.bsky.social · 02/04/2025
🚀 Exciting moments at #HydeParkCoroglio! Our Prof. Alberto Auricchio, Scientific Director at Tigem in Pozzuoli, took the stage for an inspiring talk.
100
Tigem @tigem.bsky.social · 01/04/2025
🔬 AAV-based gene therapy for Stargardt disease is safe and effective in large animal models A work of #IvanaTrapani and #AAVantgardeBio !!! 📄 #ScienceAdvances | doi.org/10.1126/sciadv.adt9354 #GeneTherapy #Ophthalmology #AAV #Stargardt #VisionResearch
doi.org
Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models
AAV-intein-based gene therapy for Stargardt disease proves to be safe and efficacious in large animal models.
000
Tigem @tigem.bsky.social · 01/04/2025
Low doses? 🎯 Boost memory. High doses? 🚫 Impair it. A game-changer for cognitive enhancement strategies in schizophrenia and beyond! 🔗Read the full article here: doi.org/10.1038/s414... #Neuroscience #Memory #Dopamine #Striatum #PKA #Schizophrenia #SystemsPharmacology
doi.org
Cortico-striatal circuit mechanisms drive the effects of D1 dopamine agonists on memory capacity in mice through cAMP/PKA signalling - Nature Communications
D1 receptor agonists bidirectionally regulate working memory capacity (WMC). Here, the authors show that low doses enhance WMC by activating cAMP/PKA in the striatum, whereas high doses impair it via ...
000
Tigem @tigem.bsky.social · 01/04/2025
🌟New Research Alert🌟 🧠 Cutting-edge neuroscience from De Leonibus' group, now in #NatureCommunications! This study reveals how different doses of D1 dopamine agonists bidirectionally regulate memory capacity via fronto-striatal cAMP/PKA signaling in mice.
doi.org
Cortico-striatal circuit mechanisms drive the effects of D1 dopamine agonists on memory capacity in mice through cAMP/PKA signalling - Nature Communications
D1 receptor agonists bidirectionally regulate working memory capacity (WMC). Here, the authors show that low doses enhance WMC by activating cAMP/PKA in the striatum, whereas high doses impair it via ...
110
Tigem @tigem.bsky.social · 20/03/2025
📣 We are hiring!!! 📣 Don't miss your chance to join TIGEM and be part of groundbreaking research! 🔬 🚨Exciting Postdoctoral Opportunity in Gene Therapy & Genome Editing! 🚨 👉 www.tigem.it/newsroom/car... 🚨Research Technician in Gene Therapy & Genome Editing🚨 👉 www.tigem.it/newsroom/car...
tigem.it
Postdoctoral Fellow Position in Gene Therapy and Genome Editing – Trapani Lab (TIGEM)
020
Reposted by Tigem
di Bernardo Lab @diegodibi.bsky.social · 17/03/2025
Here is our latest paper in @commsbio.bsky.social We reveal a two-phase TFEB nuclear shuttling driven by calcium release and mTORC1 inhibition, using microfluidics & quantitative modelling. Kudos to Iacopo Ruolo & colleagues@snapolit.bsky.social @tigem.bsky.social www.nature.com/articles/s42...
nature.com
Investigation of dynamic regulation of TFEB nuclear shuttling by microfluidics and quantitative modelling - Communications Biology
Mathematical modelling and real-time microfluidics-based measurements of nuclear shuttling dynamics of the transcription factor EB (TFEB) demonstrate its biphasic nature in response to nutrient depriv...
032
Tigem @tigem.bsky.social · 12/03/2025
#liverfibrosis #AAV #genetherapy
000
Tigem @tigem.bsky.social · 12/03/2025
🌟Importantly, the study identifies AAV-KP1 as a promising capsid variant that maintains efficient transduction even in fibrotic livers, suggesting a potential strategy for expanding gene therapy applications to fibrotic liver diseases. 📖Read the full article here! www.nature.com/articles/s41...
nature.com
Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes - Nature Communications
Ferriero et al. show that liver fibrosis reduces the efficiency of AAV-based gene therapy by limiting liver uptake and altering vector distribution to other organs. The impact of fibrosis varies depen...
120
Tigem @tigem.bsky.social · 12/03/2025
🔬 The study highlights that liver fibrosis: ✔️ Significantly reduces the efficiency of AAV8-mediated hepatocyte transduction ✔️ Alters vector biodistribution, redirecting AAV particles to the spleen, lung, and kidney ✔️ Affects gene transfer efficiency based on the fibrosis type and severity
100
Tigem @tigem.bsky.social · 12/03/2025
🚨 The latest study from #NatureCommunications, led by Pasquale Piccolo, systematically evaluated AAV-mediated liver transduction across different fibrosis models.
174
Reposted by Tigem
di Bernardo Lab @diegodibi.bsky.social · 11/03/2025
I am excited to help organize #mSBW2025. I hope you can join me and my lab to explore latest advances in this field. Learn more at www.aiche.org/sbe/conferen...
021
Tigem @tigem.bsky.social · 08/03/2025
🌟New Research Alert🌟 🔬 Exciting findings from Galietta's group, published in #JPhysiology! This study uncovers how the apical mucus layer alters drug efficacy in the airway epithelium, impacting CFTR inhibition in cystic fibrosis research. 📖Read here: physoc.onlinelibrary.wiley.com/doi/full/10....
031
Tigem @tigem.bsky.social · 07/03/2025
🌟New Research Alert 🌟 🔬 We are thrilled to share a groundbreaking study by De Matteis’s group, published in #LifeScienceAlliance, which uncovers a crucial link between mitochondrial dysfunction and protein aggregation in ALS8. 📖Read the article here: www.life-science-alliance.org/content/8/4/...
030
Reposted by Tigem
mentor-program.bsky.social @mentor-program.bsky.social · 06/03/2025
🚀 PhD Opportunity – NC-mTORC1 & Genetic Diseases! Join @tigem.bsky.social & Univ. of Naples to explore Non-Canonical mTORC1 signaling in mTORopathies like BHD & TSC!
122
Tigem @tigem.bsky.social · 05/03/2025
🚀 Our mission 🧬 Our mission is to push scientific boundaries through cutting-edge research, innovative therapies, and training the next generation of biomedical experts. Learn more: www.tigem.it ✨ #Genetics #RareDiseases #MedicalResearch
031